HomePTKFF • OTCMKTS
add
Kalbe Farma Tbk PT
Nakaraang pagsara
$0.095
Sakop ng taon
$0.087 - $0.11
Market cap
68.91T IDR
Average na Volume
62.00
P/E ratio
-
Dividend yield
-
Primary exchange
IDX
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (IDR) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 7.91T | 7.16% |
Gastos sa pagpapatakbo | 2.29T | 15.55% |
Net na kita | 573.28B | 6.97% |
Net profit margin | 7.25 | -0.14% |
Kita sa bawat share | 12.41 | 7.73% |
EBITDA | 874.81B | 1.14% |
Aktuwal na % ng binabayarang buwis | 23.01% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (IDR) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 4.32T | 45.45% |
Kabuuang asset | 28.75T | 5.78% |
Kabuuang sagutin | 4.84T | 0.67% |
Kabuuang equity | 23.91T | — |
Natitirang share | 46.15B | — |
Presyo para makapag-book | 0.00 | — |
Return on assets | 6.15% | — |
Return on capital | 7.16% | — |
Cash Flow
Net change in cash
| (IDR) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 573.28B | 6.97% |
Cash mula sa mga operasyon | 1.16T | 22.56% |
Cash mula sa pag-invest | -176.64B | 33.78% |
Cash mula sa financing | -421.11B | 51.91% |
Net change in cash | 481.86B | 1,978.42% |
Malayang cash flow | 752.00B | 13.84% |
Tungkol
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise.
The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, distribution arm that reaches over 1 million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient.
Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Prenagen, Extra Joss and Fitbar.
Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. Wikipedia
Itinatag
Set 10, 1966
Website
Mga Empleyado
12,924
